Direct comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure.

Selvais, Philippe;Ahn, Sylvia;Robert, Annie;Vanlinden, François;Rousseau, Michel;et.al.
(2000) Journal of Cardiac Failure — Vol. 6, n° 3, p. 201-207 (2000)

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 58.49 KB

Details

Authors
  • Selvais, Philippe
    Author
  • Ahn, SylviaUCLouvain
    Author
  • Robert, AnnieUCLouvain
    Author
  • Vanlinden, FrançoisUCLouvain
    Author
  • Ketelslegers, Jean-MarieUCLouvain
    Author
  • Rousseau, MichelUCLouvain
    Author
Show more
Abstract
BACKGROUND: Endothelin-1 (ET-1) and cardiac natriuretic peptide plasma concentrations have prognostic significance in congestive heart failure (CHF). However, their respective prognostic values in this setting have never been directly compared. METHODS AND RESULTS: We studied the prognostic performances of ET-1, N-terminal proatrial natriuretic factor (N-proANF), and brain natriuretic peptide (BNP) to predict the long-term cardiac mortality in fully treated patients with CHF. Peripheral plasma concentrations of the 3 peptides were measured in 109 patients (left ventricular ejection fraction [LVEF] < 35%) in New York Heart Association (NYHA) functional classes II (n = 65) or III to IV (n = 44). The outcome of the patients was evaluated 3 years after the beginning of the study, and a Cox regression model was used to identify predictors of death. Plasma concentrations of the 3 peptides increased with the severity of heart failure. By univariate analysis, 6 parameters were significantly associated with death during follow-up: ET-1 level, NYHA classes III to IV, N-proANF level, BNP level, LVEF, and age (all P < .01). By multivariate analysis, only ET-1 level and, to a lesser extent, N-proANF level contributed significantly and independently to risk stratification (chi2 = 53.4 and 12.8; P < .0001 and P < .001, respectively). CONCLUSION: In a group of patients in whom the vast majority were administered angiotensin-converting enzyme inhibitor therapy, plasma ET-1 and N-proANF concentrations identify better than several clinical markers a very high-risk group, fairly amenable to heart transplantation or new therapies.
Affiliations

Citations

Selvais, P., Ahn, S., Robert, A., Vanlinden, F., Ketelslegers, J.-M., Pouleur, H., & Rousseau, M. (2000). Direct comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure. Journal of Cardiac Failure, 6(3), 201-207. https://doi.org/10.1054/jcaf.2000.8833 (Original work published 2000)